Abnormal kidney function or use of diuretics may influence test results. This test should not be performed on individuals with kidney disorders.
The Bone Resorption Assessment is a simple urinary test that provides an accurate assessment of the rate of bone turnover in an individual. The Bone Resorption Assessment allows the practitioner to identify those more likely to develop osteoporosis, to intervene before significant loss has occurred, and to monitor the efficacy of treatment regimens. It examines pyridinium crosslinks and deoxypyridinoline and is useful in identifying current rate of bone loss, lytic bone disease, and efficacy of bone support therapies.
Hormone Testing and Osteoporosis:
- Osteoporosis leads to 1.5 million fractures per year
- Osteoporosis affects more than 50% of healthy American women aged 30-40 who are likely to develop vertebral fractures as they age
- Hormone testing is an important component to identify individuals currently losing bone at an accelerated rate so that effective treatment can begin before significant bone loss has occurred
Why is this test important?
Next to cardiovascular disease, osteoporosis is the most common disease affecting women in the U.S. today. More than 50% of healthy American women aged 30-40 are at risk of developing fractures as they age due to osteoporosis. Bone loss usually begins as early as the fourth decade of life. Early assessment and intervention is essential for preventing osteoporosis in later years. Unlike bone scans,this test can identify current levels of bone resorption. This is the most specific bone resorption analysis available. Many factors influence bone resorption. This test is useful in monitoring the effectiveness of calcium supplementation, biphosphonate therapy, and other treatment programs.
